Biren Amin Analyst PerformanceSr. Research Analyst at Piper SandlerBiren Amin is a stock analyst at Piper Sandler in the healthcare sector, covering 39 publicly traded companies. Over the past year, Biren Amin has issued 31 stock ratings, including buy and hold recommendations. While full access to Biren Amin's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Biren Amin's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings110 Last 11 YearsBuy Recommendations81.65% 89 Buy RatingsCompanies Covered39 Unique Companies Ratings Distribution109RatingsDistribution of strong buy, buy, hold, and sell ratings by Biren Amin.RatingPercentageCount Strong Buy0.0%0 ratings Buy81.7%89 ratings Hold17.4%19 ratings Sell0.9%1 ratingsOut of 109 total stock ratings issued by Biren Amin at Piper Sandler, the majority (81.7%) have been Buy recommendations, followed by 17.4% Hold and 0.9% Sell.Best & Worst CallsBest Call0000.0%ACRSJul 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%ADVMJun 2015Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ97.4% of companies on NASDAQ38 companiesNYSEAMERICAN2.6% of companies on NYSEAMERICAN1 companyBiren Amin, an analyst at Piper Sandler, currently covers 39 companies listed on NASDAQ and NYSEAMERICAN, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare39 companies100.0%Biren Amin of Piper Sandler specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY31 companies79.5%PHARMACEUTICALS8 companies20.5% About Biren AminBiren Amin is a managing director and senior research analyst on the healthcare equity research team covering biotechnology companies. Prior to joining Piper Sandler, Amin served as the chief financial officer and chief strategy officer at Pyramid Biosciences, a private biotechnology company, where he was responsible for investor relations, capital raising and leading business development activities including monitoring key competitors for therapeutics targeting solid tumors. Before Pyramid Biosciences, Amin served as the chief financial officer at Immuneering Corporation, a public clinical-stage oncology company. He previously spent 10 years at Jefferies Financial Group Inc. covering small and mid-cap biotechnology companies focused on oncology, central nervous system disorders, ophthalmology and rare diseases. Prior to Jefferies Financial Group Inc., Amin spent seven years in various equity research roles covering the biotechnology sector. Amin graduated from University of the Sciences with a bachelor's degree in pharmacy. He received his master's degree from Long Island University and his Master of Business Administration degree from the Leonard Stern School of New York University.Follow on LinkedIn Biren Amin's Ratings History at Piper Sandler Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsNERVMinerva Neurosciences8/14/2026Upgrade$3.92$10.00Mixed$0.0000.00% ROILENZLENZ Therapeutics8/12/2026Lower Price Target$5.21$7.00Neutral$0.0000.00% ROIJSPRJasper Therapeutics8/12/2026Initiated Coverage$0.89$2.00Overweight$0.0000.00% ROIJSPRJasper Therapeutics8/12/2026Initiated Coverage$0.82$2.00Overweight$0.0000.00% ROICATXPerspective Therapeutics8/11/2026Lower Price Target$3.00$14.00Overweight$0.0000.00% ROIBBIOBridgeBio Pharma8/11/2026Boost Price Target$84.67$115.00Overweight$0.0000.00% ROICMPXCompass Therapeutics8/7/2026Boost Price Target$2.15$6.00Overweight$0.0000.00% ROISRPTSarepta Therapeutics7/9/2026Lower Price Target$20.32$20.00Neutral$0.0000.00% ROIREGNRegeneron Pharmaceuticals7/9/2026Lower Price Target$664.12$854.00Overweight$0.0000.00% ROICNTBConnect Biopharma6/26/2026Initiated Coverage$2.07$7.00Overweight$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. CNTBConnect Biopharma6/26/2026Initiated Coverage$2.21$7.00Overweight$0.0000.00% ROIREGNRegeneron Pharmaceuticals5/18/2026Lower Price Target$623.32$855.00Overweight$0.0000.00% ROISLDBSolid Biosciences5/13/2026Reiterated Rating$7.72$18.00Overweight$0.0000.00% ROILENZLENZ Therapeutics5/12/2026Downgrade$9.99$12.00Neutral$0.0000.00% ROIACRSAclaris Therapeutics5/5/2026Boost Price Target$4.53$11.00Overweight$0.0000.00% ROIREGNRegeneron Pharmaceuticals3/31/2026Initiated Coverage$749.29$875.00Overweight$0.0000.00% ROICNTXContext Therapeutics3/24/2026Boost Price Target$3.02$7.00Overweight$0.0000.00% ROIIMTXImmatics3/16/2026Initiated Coverage$9.71$18.00Buy$0.0000.00% ROIALLOAllogene Therapeutics3/13/2026Boost Price Target$2.39$8.00Overweight$0.0000.00% ROIKYMRKymera Therapeutics2/26/2026Boost Price Target$89.09$140.00Overweight$0.0000.00% ROIOKYOOKYO Pharma2/20/2026Initiated Coverage$1.76$7.00Overweight$0.0000.00% ROIOKYOOKYO Pharma2/20/2026Initiated Coverage$1.70$7.00Overweight$0.0000.00% ROICATXPerspective Therapeutics2/19/2026Initiated Coverage$5.03$16.00Overweight$0.0000.00% ROICATXPerspective Therapeutics2/19/2026Initiated Coverage$5.65$16.00Overweight$0.0000.00% ROIIRDOpus Genetics11/25/2025Initiated Coverage$2.00$7.00Overweight$0.0000.00% ROIAAPGAscentage Pharma Group International11/5/2025Initiated Coverage$33.25$48.00Overweight$0.0000.00% ROISRPTSarepta Therapeutics10/30/2025Boost Price Target$23.20$16.00Neutral$0.0000.00% ROIBBIOBridgeBio Pharma10/30/2025Boost Price Target$65.44$98.00Overweight$0.0000.00% ROILENZLENZ Therapeutics10/10/2025Boost Price Target$46.25$67.00Overweight$0.0000.00% ROIOCULOcular Therapeutix10/3/2025Boost Price Target$11.06$31.00Overweight$0.0000.00% ROIMNPRMonopar Therapeutics9/25/2025Set Price Target$72.87$95.00Overweight$0.0000.00% ROISRPTSarepta Therapeutics7/29/2025Boost Price Target$13.86$15.00Neutral$00.0000.00% ROIKLRSKalaris Therapeutics7/23/2025Set Price Target$2.57$3.00Neutral$0.0000.00% ROISRPTSarepta Therapeutics7/21/2025Lower Price Target$13.79$18.00Neutral$00.0000.00% ROIBBIOBridgeBio Pharma7/14/2025Boost Price Target$46.47$68.00Overweight$00.0000.00% ROIACRSAclaris Therapeutics7/10/2025Initiated Coverage$1.62$6.00Overweight$0.0000.00% ROICNTXContext Therapeutics6/26/2025Reiterated Rating$0.64$4.00Overweight$0.0000.00% ROISRPTSarepta Therapeutics6/16/2025Downgrade$36.18$36.00Neutral$00.0000.00% ROISLDBSolid Biosciences5/16/2025Lower Price Target$2.84$17.00Overweight$0.0000.00% ROIALLOAllogene Therapeutics5/14/2025Lower Price Target$0.93$7.00Overweight$0.0000.00% ROIA letter from Shannon Stansberry (Ad)Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.Watch the full story and see the verified track record for yourselfSRPTSarepta Therapeutics5/7/2025Lower Price Target$38.37$70.00Overweight$00.0000.00% ROIBBIOBridgeBio Pharma4/30/2025Boost Price Target$38.50$63.00Overweight$00.0000.00% ROISRPTSarepta Therapeutics4/21/2025Lower Price Target$53.62$110.00Overweight$00.0000.00% ROILENZLENZ Therapeutics4/14/2025Initiated Coverage$21.95$51.00Overweight$0.0000.00% ROICNTACentessa Pharmaceuticals3/31/2025Initiated Coverage$14.59$38.00Overweight$00.0000.00% ROICMPXCompass Therapeutics2/19/2025Initiated Coverage$3.17$12.00Overweight$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenWeiss RatingsCitigroupUBS GroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank Aktiengesellschaft Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.